Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 60687-607

9 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 60687-607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp60721

Ahp60721
Desvenlafaxine 50 mg extended-release film-coated oral tablet, round and light beige in color. One side is imprinted with the code '54 716', and the other side is plain without markings. Manufactured by American Health Packaging.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of desvenlafaxine showing its molecular components including hydroxyphenyl, cyclohexanol, and dimethylamino groups, alongside oxalic acid and a water molecule.*
FDA Label Image

Figure 1: Impact Of Intrinsic Factors (renal, Hepatic Impairment And Population Description) On Desvenlafaxine Pharmacokinetics (Figure 1)

Figure 1: Impact Of Intrinsic Factors (renal, Hepatic Impairment And Population Description) On Desvenlafaxine Pharmacokinetics (Figure 1)
A chart presenting geometric mean ratios (90% confidence intervals) of Cmax and AUC for Desvenlafaxine across various renal and hepatic impairment levels and population subgroups. The x-axis shows the change relative to reference with values ranging from 0.5 to 3.5. Data categories include mild, moderate, severe, and ESRD for renal impairment; mild to severe for hepatic impairment; and gender and age groups for population description.*
FDA Label Image

Figure 2: Effect Of Other Drugs On Desvenlafaxine Pharmacokinetics (Figure 2)

Figure 2: Effect Of Other Drugs On Desvenlafaxine Pharmacokinetics (Figure 2)
A pharmacokinetic chart showing the geometric mean ratio and 90% confidence interval of changes in Cmax and AUC for Desvenlafaxine with CYP3A4 inhibitor Ketoconazole. The chart indicates changes relative to reference values with a scale from 0.5 to 2.0.*
FDA Label Image

Figure 3: Effects Of Desvenlafaxine On Pharmacokinetics Of Other Drugs (Figure 3)

Figure 3: Effects Of Desvenlafaxine On Pharmacokinetics Of Other Drugs (Figure 3)
A forest plot showing the geometric mean ratio (90% confidence interval) for pharmacokinetic parameters (Cmax, AUC) of various interacting drugs when co-administered with Desvenlafaxine (Pristiq) at different doses (50 mg, 100 mg, 400 mg). Drugs include Desipramine, Midazolam, Tamoxifen, and Aripiprazole with corresponding PK values and changes relative to reference indicated by markers and error bars along a horizontal axis ranging from 0.5 to 2.5.*
FDA Label Image

Figure 4: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 5) (Figure 4)

Figure 4: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 5) (Figure 4)
A line graph depicting the estimated proportion of patients experiencing relapse over time (days from randomization) comparing Desvenlafaxine 50 mg versus placebo. The x-axis represents time up to 200 days, and the y-axis shows the relapse percentage up to 50%. The Desvenlafaxine 50 mg group shows a consistently lower relapse proportion than the placebo group throughout the timeline.*
FDA Label Image

Figure 5: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 6) (Figure 5)

Figure 5: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 6) (Figure 5)
A Kaplan-Meier curve comparing the estimated proportion of patients with relapse over time (days from randomization) between Desvenlafaxine and placebo groups. The graph shows relapse proportions on the y-axis and time up to 180 days on the x-axis, with Desvenlafaxine represented by a solid line and placebo by a dashed line.*
FDA Label Image

50 mg Desvenlafaxine Tablets Carton.jpg (50 mg Desvenlafaxine Tablets Carton)

50 mg Desvenlafaxine Tablets Carton.jpg (50 mg Desvenlafaxine Tablets Carton)
Label for Desvenlafaxine extended-release tablets, 50 mg strength, in a package of 30 tablets (3 x 10). The label includes dosage form, strength, NDC 60687-607-21, and manufacturer American Health Packaging. Additional information includes pharmacist instructions, storage conditions, and a QR code for medication guide and prescribing information.*
FDA Label Image

50 mg Desvenlafaxine Er Tablet Blister.jpg (50 mg Desvenlafaxine Er Tablet Blister)

50 mg Desvenlafaxine Er Tablet Blister.jpg (50 mg Desvenlafaxine Er Tablet Blister)
Desvenlafaxine 50 mg extended-release film-coated tablets packaging label from American Health Packaging. The label displays the proprietary name, dosage strength, lot number 1234567, and expiration date 2023-10-23. The label includes barcodes and standard product information repeated six times on the sheet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.